Document Detail


Myocardial Perfusion Reserve After a PET-Driven Revascularization Procedure: A Strong Prognostic Factor.
MedLine Citation:
PMID:  21571798     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Not all patients treated on the basis of PET-proven viability benefit from revascularization. Myocardial perfusion reserve (MPR) predicts survival in patients not undergoing revascularization. In the present study, we investigated whether MPR is related to survival in ischemic heart disease (IHD) patients after a PET-driven intervention. METHODS: Between 1995 and 2003, 119 consecutive patients with chronic IHD underwent a PET-driven revascularization procedure based on ischemia-viability assessment with PET. Patients were followed for all-cause mortality and major cardiovascular events. RESULTS: One hundred nineteen patients underwent a PET-driven revascularization procedure (67 percutaneous coronary interventions, 52 coronary artery bypass grafts) because of angina complaints. The mean age was 67 ± 11 y (96 men, 23 women); global left ventricle MPR was 1.54 ± 0.43. MPR intertertile boundaries were 1.34 and 1.67. Significantly more cardiac deaths were observed in the lowest and middle MPR tertiles than in the highest tertile. The age- and sex-corrected hazard ratio for the middle tertile was 8.3 (95% confidence interval, 1.02-68.3) and for the lowest tertile 23.6 (95% confidence interval, 3.1-179) (P = 0.002). After left ventricular ejection fraction (LVEF) and viability were added to the model, MPR remained significant, with hazard ratios of 6.5 (0.8-54.4) and 18.5 (2.3-145.5) (P = 0.004), whereas neither LVEF nor viability reached significance in this model. Comparable results were found for major adverse cardiac events, with hazard ratios of 3.15 (0.82-12.0) and 8.24 (2.36-28.8) (P = 0.002). CONCLUSION: Patients with IHD revascularized on the basis of PET viability assessment who have a low MPR are at risk for cardiac death and subsequent cardiac events. MPR is a more sensitive predictor for cardiac death than LVEF and extent of viability.
Authors:
Riemer H J A Slart; Clark J Zeebregts; Hans L Hillege; Johan de Sutter; Rudi A J O Dierckx; Dirk J van Veldhuisen; Felix Zijlstra; René A Tio
Related Documents :
11497208 - Ongoing trials of angiotensin-converting enzyme inhibition: what they can tell us.
22119118 - Relationship of cardiac biomarkers and reversible and irreversible myocardial injury fo...
22198008 - Allograft pathology in patients transplanted for idiopathic dilated cardiomyopathy.
22742868 - Transesophageal echocardiography and cardioversion trends in patients with atrial fibri...
2802288 - Cpr-dependent consciousness: evidence for cardiac compression causing forward flow.
16082438 - Device closure of a patent foramen ovale in a patient with lipomatous hypertrophy of th...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-13
Journal Detail:
Title:  Journal of nuclear medicine : official publication, Society of Nuclear Medicine     Volume:  -     ISSN:  1535-5667     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0217410     Medline TA:  J Nucl Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment.
Next Document:  Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumom...